See more : Tootsie Roll Industries, Inc. (TROLB) Income Statement Analysis – Financial Results
Complete financial analysis of Celcuity Inc. (CELC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celcuity Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Gudang Garam Tbk (GGRM.JK) Income Statement Analysis – Financial Results
- Metro Performance Glass Limited (MPP.AX) Income Statement Analysis – Financial Results
- Hat Trick Beverage, Inc. (HKBV) Income Statement Analysis – Financial Results
- Shenzhen Investment Holdings Bay Area Development Company Limited (SHIHF) Income Statement Analysis – Financial Results
- Luxor Industrial Corporation (LXRRF) Income Statement Analysis – Financial Results
Celcuity Inc. (CELC)
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| Gross Profit | -142.77K | -210.92K | -303.24K | -385.59K | -339.00K | -223.04K | -104.70K | -73.06K | -58.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.59M | 35.29M | 25.76M | 7.68M | 6.27M | 6.33M | 4.98M | 3.06M | 2.01M |
| General & Administrative | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Cost & Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Interest Income | 2.45M | 1.13M | 13.26K | 82.11K | 446.10K | 448.83K | 152.88K | 18.02K | 268.00 |
| Interest Expense | 0.00 | 2.11M | 1.26M | 120.00 | 159.00 | 111.00 | 451.66K | 0.00 | 0.00 |
| Depreciation & Amortization | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| EBITDA | -58.31M | -39.18M | -28.05M | -9.17M | -7.47M | -7.71M | -5.85M | -3.26M | -2.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -66.23M | -39.39M | -28.36M | -9.56M | -7.81M | -7.93M | -5.95M | -3.33M | -2.26M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | -978.95K | -1.25M | 81.99K | 445.94K | 451.72K | -298.79K | 18.02K | 268.00 |
| Income Before Tax | -63.78M | -40.37M | -29.61M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M | -2.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 978.95K | 959.12K | -385.47K | -338.84K | 451.83K | 48.18K | 0.00 | 0.00 |
| Net Income | -63.78M | -41.35M | -30.56M | -9.09M | -7.02M | -7.48M | -6.25M | -3.31M | -2.26M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| EPS Diluted | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Weighted Avg Shares Out | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
| Weighted Avg Shares Out (Dil) | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted gedatolisib Breakthrough...
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet
The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder...
Celcuity Inc. (CELC) CEO Brian Sullivan on Q1 2022 Results - Earnings Call Transcript
Celcuity Inc. (NASDAQ:CELC ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder, Chairman & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call...
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
Entered into $100 Million Private Placement Agreement Finalized pivotal Phase 3 trial design for gedatolisib Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer Management to host webcast and conference call today, May 16, 2022, at 4:30...
Celcuity Inc. Announces $100 Million Private Placement
Proceeds to Advance Clinical Development of Gedatolisib Including Forthcoming Phase 3 Clinical Study (VIKTORIA-1) MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating...
Lafarge Canada s'apprête à doubler les volumes de granulats recyclés par le biais de partenariats clés
MISSISSAUGA, Ontario--(BUSINESS WIRE)--En l'honneur du Jour de la Terre (22 avril), Lafarge Canada Inc. est fier d'annoncer l'objectif ambitieux de doubler les volumes de granulats recyclés de l'Est du Canada d'ici 2025 – avec pour mission de fournir aux clients...
Lafarge Canada to Double Recycled Aggregates Volumes Through Key Partnerships
MISSISSAUGA, Ontario--(BUSINESS WIRE)--In celebration of this year’s Earth Day (April 22), Lafarge Canada Inc. is proud to announce the ambitious goal of doubling Eastern Canada Recycled Aggregates volumes by 2025 – a set target to supply customers with over 2...
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder...
Source: https://incomestatements.info
Category: Stock Reports